

**THE CHALLENGE OF INFRAPOPLITEAL DISEASE:
CHARACTERISTICS,
RESTENOSIS AFTER ENDOVASCULAR REVASCULARIZATION AND
REVIEW OF SEVERAL NEW TECHNOLOGIES**

Mary L. Yost
404-520-6652
THE SAGE GROUP

THE SAGE GROUP, LLC
RESEARCH AND CONSULTING
23 Ridge Rd
Beaufort SC 29907

Copyright Pending
2023

All rights reserved, including the right of reproduction
in whole or in part in any form.

Table of Contents

SUMMARY AND CONCLUSIONS	6
Characteristics of Infrapopliteal Disease	6
Treatment Challenges	7
Predictors of Restenosis	7
Consequences of Restenosis	8
Quality and Quantity of the Data	8
Conclusions: Incidence of Infrapopliteal Restenosis	8
Limitations	9
Conclusions: Restenosis Rate in Meta-Analyses	9
Limitations	10
Conclusions Regarding Device Superiority in Meta-Analyses	10
Which Device Has the Lowest Restenosis Rate in Treating Infrapopliteal Disease?...	10
INTRODUCTION	11
INFRAPOPLITEAL DISEASE	11
Primarily Afflicts Critical Limb Ischemia Patients	12
Multilevel Interventions.....	12
Isolated Infrapopliteal Disease is Common	12
Pedal Arteries Frequently Diseased	12
Treatment Challenges	12
Medial Artery Calcification Predominates	13
TRANSATLANTIC INTER-SOCIETY CONSENSUS (TASC)	
INFRAPOPLITEAL CLASSIFICATION SYSTEM	13
Lesion Morphology Varies by TASC Type.....	14
TASC C and D Lesions Predominate	14
PERCUTANEOUS TRANSLUMINAL BALLOON ANGIOPLASTY—THE	
STANDARD OF CARE	15
Suboptimal Outcomes Characterized by High Rates of Restenosis and Frequent	
Reinterventions	15
RESTENOSIS	15
Restenosis Defined as Target Lesion Revascularization	15
Causes	15
Elastic Recoil	15
Neointimal Hyperplasia	16
Predictors of Restenosis	16
Femoropopliteal Interventions	16
Infrapopliteal Interventions.....	16
Restenosis is Not Benign	17
Multiple Reinterventions Needed	17
High Morbidity and Mortality	18
Poor Ambulatory Status and Discharge Location.....	18
Increased Costs	18
RESTENOSIS AFTER PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY 18	
Target Lesion Revascularization Rate in Clinical Trials and Registries	18
Long-Term Results	19
Limitations	19

Pooled Target Lesion Revascularization Rate in Meta-Analyses	20
RESTENOSIS AFTER BARE METAL STENT (BMS) IMPLANTATION.....	21
Concerns About Infrapopliteal Stenting	21
Target Lesion Revascularization Rate in Clinical Trials and Registries	21
Long-Term Results	21
Limitations	22
Pooled Target Lesion Revascularization Rate in Meta-Analyses.....	23
RESTENOSIS AFTER DRUG-ELUTING STENT (DES) IMPLANTATION.....	24
Target Lesion Revascularization Rate in Clinical Trials and Registries	24
PADI Trail	25
Limitations	25
Pooled Target Lesion Revascularization Rate in Meta-Analyses.....	26
Disappointing Results Reported for Dedicated Infrapopliteal Drug-Eluting Stent	27
RESTENOSIS AFTER TREATMENT WITH DRUG-COATED BALLOON	
(DCB)	28
Target Lesion Revascularization Rate in Clinical Trials and Registries	28
Limitations	29
Pooled Target Lesion Revascularization Rate in Meta-Analyses.....	31
INCONSISTENT TRIAL RESULTS WITH PACLITAXEL-COATED	
BALLOONS (PCB).....	31
Drug-Coated Balloons are Not Interchangeable	32
Differences in Study Design	32
Variations in Lesion Preparation	33
Differences in the Amount of Paclitaxel Transferred to the Lesion	33
Variations in Drug-Coated Balloon Inflation Time	33
Suboptimal Sizing.....	33
Drug Loss and Transit Time	34
Slow-Flow Due to Paclitaxel Embolization.....	34
Angiography May Overstate Efficacy of Percutaneous Transluminal Angioplasty.....	34
Other Factors Affecting Outcomes	35
COMPARISON OF TARGET LESION REVASCULARIZATION RATE BY	
DEVICE TYPE	35
Comparison of Twelve-Month Target Lesion Revascularization Rate by Device	35
Are Coronary Drug-Eluting Stents Superior in Short Lesions?.....	36
Drug-Coated Balloon Outcomes Equivocal.....	37
Limitations	38
Small Number of Drug-Coated Balloon Patients.....	38
Outsized Effect of IN.PACT DEEP Trial	38
RESTENOSIS AFTER TREATMENT WITH ATHERECTOMY	38
Atherectomy Plus Angioplasty	38
Randomized Controlled Trials	38
Single Center and Registry Studies.....	38
Meta-Analyses	39
Complications and Reinterventions May be Higher.....	39
Atherectomy Plus Drug-Coated Balloon versus Drug-Coated Balloon	39
Meta-Analyses	40

Limitations in Comparing Atherectomy Outcomes	40
DRUG DELIVERY DEVICES.....	40
Pressana Occlusion Perfusion Catheter	40
Bullfrog Micro-Infusion Device	41
INTRAVASCULAR LITHOPLASTY, SIROLIMUS-COATED BALLOONS	
AND BIORESORBABLE VASCULAR SCAFFOLDS	41
INFRAPOPLITEAL TREATMENT WITH INTRAVASCULAR	
LITHOPLASTY.....	41
SIROLIMUS-COATED BALLOONS (SCB).....	42
Advantages of Sirolimus.....	42
Balloon Coating Challenges	42
Devices with Infrapopliteal Data	42
MagicTouch	43
Selution Sustained Limus Release (SLR).....	44
Sundance.....	44
Virtue AngioInfusion Balloon	44
BIORESORBABLE VASCULAR SCAFFOLD	45
Device Description.....	45
Results of First Generation Devices for Treatment of Infrapopliteal Disease.....	45
Absorb Bioresorbable Vascular Scaffold.....	45
Coronary Experience	46
Infrapopliteal Data	46
BioMatrix Flex Biolimus A9-Eluting Stent.....	46
Magic Absorbable Metal Stent	47
Meta-Analysis of Three Different Scaffolds.....	47
In Coronary Arteries Optimal Implantation Technique Affects Outcomes.....	47
Infrapopliteal Usage Might be Limited by Lesion Characteristics.....	48
Device Designs and Materials	48
Next Generation Devices in Clinical Trials for Infrapopliteal Disease	48
Feature Thinner Struts.....	49
Easier to Deliver and Use	49
Encouraging Initial Results.....	50
Devices for Femoropopliteal Disease	50
REFERENCES.....	51
INDEX OF TABLES	67
APPENDIX: CLINICAL TRIAL AND REGISTRY ACRONYMS.....	69
CONTACT INFORMATION.....	72

CONTACT INFORMATION

Mary L. Yost
President
Telephone (404) 520-6652
yost@thesagegroup.us